noth new today call system go axion reiter overweight rate call
note call noth new gener manag call seri today brook stori vice-president
gener manag pelvic health gastric therapi view overweight rate unchang
 oo bloomberg im reach via im email call ith question kristen
kstew call note medtron gm call seri pelvic health focu
big market barrier market develop peopl global ith incontin
popul less affect access advanc therapi first line lifestyl therapi physic
therapi patient get prescript drug patient get third line therapi hich advanc therapi
regard prescript drug patient take medic stop ithin month side effect given
barrier condit hard patient talk focus build aw are
therapi term market grow th see solid mid-singl digit grow th ith opportun acceler new
technolog come addit one come market
face new competit compet differenti pioneer space
year ago portfolio interstim ii also nuro hich percutan tibial neuromodul new portfolio
 ill differenti via number thing
first batteri overdr batteri technolog ith interstim micro design miniatur
manufactur ith batteri drain hich differenti spinal cord stim
market interstim micro hich ill constant current ill
anoth featur ill mri elig surescan lead ill sure ith interstim micro use ith
interstim system hich recharge-fre fda submiss that differenti ell
programm launch smart program common programm pave ay digit health symptom
basic evalu lead major evalu basic evalu lead offic latest
design minim lead migrat evalu patient ill receiv access interstim ith think
 ill earli spring unit state
read research report misconcept product want address
address myth compani innov year launch three new product market
programm interstim system also launch second gener nuro system also launch tyrx
invest clinic evid lead program evalu batteri evid improv access
constant current versu constant voltag interstim ii constant voltag interstim micro ill constant current
snm function equival differ efficaci zero studi snm space tw
studi db space consensu suggest there differ efficaci offer --
recharge-fre recharg devic
recharg recharge-fre commit provid right therapi patient studi
neuromodul journal show ed patient chose recharg free hile chose recharg medtron
unit state recharg ill around recharg outsid us patient ill
like pick recharg free longer term think competit also see hy recharg
free system pipelin ell
size sale forc idea salesforc size competitor
correct commit serv patient pre- post-impl salesforc also larger
pend litig innov space year ork long
competit invest heavili built ip patent assert batteri technolog recharg system lead design
percutan deliveri comment litig strategi
mileston investor focu track receiv ce mark basic evalu lead juli great success
uk market target fda approv earli spring ce mark new interstim portfolio januari fda approv
interstim micro ith constant current interstim ith mri spring digit trial month
comment data approv reli interstim data micro extens interstim data clinic
studi stimul sacral nerv discuss date ith fda doesnt think need run studi
similar competitor axon
think growth market mid-singl digit ith new product see mid-singl
double-digit grow th market
busi technolog come think time ill short isnt first time face
competitor market pioneer give lot confid abil maintain share think doctor understand
superior technolog brought market portfolio product expect lose share
doctor tri competitor product
present share loss first realiz larg field organ remind doctor patient
commit space abil support care journey ork close ith doctor aw
timelin new technolog idea sw itch ideal doctor patient ant choic everi
candid one recharg ork ith doctor remind small six-month gap
featur import batteri superior abil choic recharg recharg free mri
elig matter make differ
mri elig compat thing use interchang interstim ii batteri today exist lead
interstim recharge-fre smaller version ye ork
pelvic health think strategi busi focu solut incontin alw ay keep eye solut
incontin absolut keep eye implant solut incontin implant tibial solut dedic
market look type innov incontin relat omen men fecal incontin ell ventur
develop market number patient still small held back adopt
lot patient could treat biggest barrier lack aw are
inform axon see follow notes/report
 oab approv race realli begin
reiter overw eight ahead immin approv anoth physician seminar
readi set go oab day physician seminar takeaw ay reit ow note review takeaw ay axon
physician seminar attend
address innov void initi ith overw eight rate note initi report contain background
inform compani review landscap snm
model post barclay live model link
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog valu axn ev/sal basi price target appli multipl sale estim
million hich compar smid cap high grow th med-tech compani
risk may imped achiev barclay research valuat price risk includ time
adopt clinician abil penetr market competit product approv time line launch particularli
interstim micro fda manufactur issu recal also risk factor reimburs chang
rate price target histori
histor stock price price target may adjust stock split dividend
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog price target
appli target pe calendar ep estim discount med-tech compani
trade hich believ appropri given slow er grow th profil grow th profil improv expect
pe expand
risk may imped achiev barclay research valuat price nside risk includ fx rate
strengthen us dollar hich could pressur earn stock perform new product key futur success
compani thu extent compani unabl receiv fda approv could advers impact futur
outlook product includ compani surgic robot platform hich expect regulatori approv outsid unit
state begin key product includ micra av interstim micro minim futur iter continu blood
glucos monitor devic transcathet valv system upsid greater success ith new product margin expans
risk includ signific reimburs chang competit pressur product failur fda govern
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
unless otherw ise indic price sourc bloomberg reflect close price relev trade market hich
may last avail price time public
